Literature DB >> 20538500

Parkinson's disease psychosis 2010: a review article.

Joseph H Friedman1.   

Abstract

Psychotic symptoms are common in Parkinson's disease (PD), generally associated with the medications used to treat the motor symptoms. On rare occasion they occur in patients not taking medication for PD. Psychotic symptoms are usually hallucinations, typically visual, less commonly auditory, and rarely in other domains. Hallucinations are generally stereotyped and without emotional content. Initially patients usually have insight so that the hallucinations are benign in terms of their immediate impact but have poor prognostic implications, with increased risk of dementia, worsened psychotic symptoms and mortality. Delusions occur in about 5-10% of drug treated patients and are considerably more disruptive, being paranoid in nature, often of spousal infidelity or abandonment by family. Treatment of Parkinson's disease psychosis (PDP) focuses on reducing the psychiatric symptom load while balancing the competing problem of mobility. Contributors to the psychotic symptoms should be searched for, such as systemic illness and other psycho-active medications. If none are identified or can be eliminated then the PD medications should be reduced to the lowest levels that allow tolerable motor function. Once this level has been reached there are two schools of thought on treatment, using either acetylcholinesterase inhibitors or atypical anti-psychotics. Only clozapine has level I evidence to support its use. Quetiapine is the only other anti-psychotic free of motor side effects, but it has failed double blind placebo controlled trials to demonstrate efficacy.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538500     DOI: 10.1016/j.parkreldis.2010.05.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  26 in total

1.  Computer-Based Visualization System for the Study of Deep Brain Structures Involved in Parkinson's Disease.

Authors:  Juan A Juanes; Pablo Ruisoto; José A Obeso; Alberto Prats; Joan San-Molina
Journal:  J Med Syst       Date:  2015-09-14       Impact factor: 4.460

2.  Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Authors:  Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2011-06-28       Impact factor: 10.338

3.  Affective Correlates of Psychosis in Parkinson's Disease.

Authors:  Stewart A Factor; Michael K Scullin; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  Mov Disord Clin Pract       Date:  2016-06-16

4.  New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.

Authors:  Michael A Kelberman; Elena M Vazey
Journal:  Curr Pharmacol Rep       Date:  2016-09-28

5.  MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Authors:  Steven M Grauer; Robert Hodgson; Lynn A Hyde
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

6.  Dementia in Parkinson's disease.

Authors:  Avrom L Kurtz; Daniel I Kaufer
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 7.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

Review 8.  New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease.

Authors:  Elena M Vazey; Gary Aston-Jones
Journal:  Brain Res       Date:  2013-01-18       Impact factor: 3.252

Review 9.  Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management.

Authors:  Clive Ballard; Dag Aarsland; Paul Francis; Anne Corbett
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

10.  New perspectives in the care of Parkinson disease.

Authors:  Irving Asher
Journal:  Mo Med       Date:  2012 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.